FDA Drug Moderate Class II Terminated

Medroxyprogesterone acetate injectable suspension, USP, 150 mg/mL, 1 mL vials, packaged in a) single dose vial (NDC 0703-6801-01), b) 25-count box single dose vials (NDC 0703-6801-04), Rx only, MFG: Teva Pharma USA

Reported: June 15, 2022 Initiated: April 13, 2022 #D-1069-2022

Product Description

Reason for Recall

cGMP deviations: Temperature abuse

Details

Recalling Firm: Mckesson Medical-Surgical Inc. Corporate Office
Units Affected: 89 cartons/25 vials per carton and 3 cartons/1 vial
Distribution: USA nationwide.
Location: Richmond, VA

Frequently Asked Questions

What product was recalled? ▼

Medroxyprogesterone acetate injectable suspension, USP, 150 mg/mL, 1 mL vials, packaged in a) single dose vial (NDC 0703-6801-01), b) 25-count box single dose vials (NDC 0703-6801-04), Rx only, MFG: Teva Pharma USA. Recalled by Mckesson Medical-Surgical Inc. Corporate Office. Units affected: 89 cartons/25 vials per carton and 3 cartons/1 vial.

Why was this product recalled? ▼

cGMP deviations: Temperature abuse

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on June 15, 2022. Severity: Moderate. Recall number: D-1069-2022.